PharmaEssentia Reports Strong BESREMi Growth and Advances Pipeline for Rare Blood Cancer Treatment
核心洞察
PharmaEssentia (搜索) achieved 44% year-over-year revenue growth for BESREMi in Q3 2025, reaching $127.8 million in quarterly revenue.
The company submitted regulatory applications for BESREMi injection pen and essential thrombocythemia (搜索) indication expansion to the FDA.
Six early-stage programs advanced to IND-enabling stage, including novel immunocytokines, ADCs, and TCR-T cell therapies for solid tumors (搜索).
PharmaEssentia (搜索) Corporation delivered substantial commercial growth in 2025, driven by strong performance of its rare blood cancer treatment BESREMi (ropeginterferon alfa-2b-njft), while advancing multiple pipeline programs toward clinical development. The Taiwan-based biopharmaceutical company reported Q3 2025 revenue of $127.8 million for BESREMi, representing 44% year-over-year growth in polycythemia vera (搜索) treatment.
Commercial Expansion and Regulatory Progress
BESREMi has established itself as a key growth driver for PharmaEssentia (搜索), currently FDA-approved for treating adults with polycythemia vera (搜索), a rare blood cancer characterized by overproduction of red blood cells. The company has strengthened its commercial and medical affairs capabilities in preparation for anticipated 2026 product launches.
"BESREMi has become a key growth engine for our company with the potential to transform treatment across multiple patient populations living with serious myeloproliferative neoplasms (搜索)," said Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia (搜索). "In 2025, we saw strong performance in polycythemia vera (搜索) and are well positioned for further acceleration."
The company submitted two critical regulatory applications to the FDA in 2025: the BESREMi injection pen presentation and a supplemental biologics license application (sBLA) seeking label expansion for essential thrombocythemia (搜索) (ET) based on positive head-to-head Phase 3 results. Essential thrombocythemia is characterized by bone marrow overproduction of platelets, putting patients at increased risk of blood clots, abnormal bleeding, and enlarged spleens.
Pipeline Development Accelerates
PharmaEssentia (搜索) advanced six high-value programs to the IND-enabling stage across multiple therapeutic areas. The pipeline includes PEG-IL-2 and P11838 (搜索) for immunology and inflammation indications, a PD-1 (搜索)–IL-2 immunocytokine for solid tumors (搜索), and a dual-targeting LILRB1 (搜索)/2 monoclonal antibody for solid tumors. The company also progressed a novel ADC candidate and KRAS (搜索) and NY-ESO (搜索) TCR-T cell therapies for solid tumor treatment.
The company continues global enrollment in its Phase 3 trial evaluating BESREMi in pre-fibrotic/early primary myelofibrosis (搜索) (Early PMF), with completion of enrollment expected in the first half of 2026.
2026 Strategic Milestones
PharmaEssentia (搜索) outlined several key anticipated milestones for 2026, including the expected U.S. launch of BESREMi Pen in the first half of the year. The company anticipates potential FDA approval and commercial launch of the ET indication in the second half of 2026, which would significantly expand the addressable patient population for BESREMi.
The company plans to file IND submissions for multiple earlier-stage pipeline programs and share initial clinical results from several programs currently in development.
Global Market Position
BESREMi holds orphan drug designation in the United States for polycythemia vera (搜索) treatment and has received regulatory approval in over 40 countries, including from the European Medicines Agency (2019), the U.S. Food and Drug Administration (2021), and the Pharmaceuticals and Medical Devices Agency in Japan (2023). PharmaEssentia (搜索) retains full global intellectual property rights across all indications.
The company, founded in 2003, operates globally with facilities in the U.S., Japan, China, and Korea, along with a biologics production facility in Taichung, Taiwan. PharmaEssentia (搜索) will present its strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026.